Get the Stockscreener App
370.49
2.02%
-7.64
After Hours:
370.49
United Therapeutics Corp stock is traded at $370.49, with a volume of 202.72K.
It is down -2.02% in the last 24 hours and up +5.01% over the past month.
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
See More
Previous Close:
$378.13
Open:
$377.46
24h Volume:
202.72K
Relative Volume:
0.59
Market Cap:
$16.54B
Revenue:
$2.76B
Net Income/Loss:
$1.11B
P/E Ratio:
20.41
EPS:
18.15
Net Cash Flow:
$898.10M
1W Performance:
-0.64%
1M Performance:
+5.01%
6M Performance:
+38.39%
1Y Performance:
+59.65%
1-Day Range:
$370.02
$379.06
1-Week Range:
$366.94
$382.26
52-Week Range:
$208.62
$417.81
United Therapeutics Corp Stock (UTHR) Company Profile
Name
United Therapeutics Corp
Sector
Industry
Phone
(301) 608-9292
Address
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
370.49 | 16.54B | 2.76B | 1.11B | 898.10M | 22.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-12-24 | Upgrade | Goldman | Sell → Neutral |
| Feb-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Dec-06-22 | Initiated | UBS | Buy |
| Dec-05-22 | Initiated | Goldman | Sell |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-20-22 | Reiterated | BofA Securities | Underperform |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Feb-11-22 | Initiated | BTIG Research | Neutral |
| Jul-14-21 | Upgrade | Argus | Hold → Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-01-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jun-25-20 | Reiterated | H.C. Wainwright | Neutral |
| Mar-10-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-27-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-31-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-03-19 | Initiated | BofA/Merrill | Underperform |
| Aug-01-19 | Upgrade | Jefferies | Underperform → Hold |
| Aug-01-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-01-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| May-17-19 | Upgrade | UBS | Sell → Neutral |
| May-09-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-12-18 | Upgrade | Standpoint Research | Hold → Buy |
| Aug-08-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-03-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-22-18 | Reiterated | Barclays | Underweight |
| Jan-18-18 | Resumed | Credit Suisse | Underperform |
| Dec-27-17 | Reiterated | Wedbush | Outperform |
| Apr-27-17 | Reiterated | Wedbush | Outperform |
| Mar-30-17 | Initiated | UBS | Sell |
| Mar-16-17 | Initiated | Credit Suisse | Underperform |
View All
United Therapeutics Corp Stock (UTHR) Latest News
United Therapeutics Co. (NASDAQ:UTHR) Holdings Trimmed by Crawford Fund Management LLC - MarketBeat
The 3.8% return this week takes United Therapeutics' (NASDAQ:UTHR) shareholders five-year gains to 314% - Yahoo Finance
Glenmede Trust Co. NA Boosts Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics president sells shares worth $3.73 million By Investing.com - Investing.com Nigeria
Dai ichi Life Insurance Company Ltd Sells 1,412 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) COO Sells 10,000 Shares of Stock - MarketBeat
United Therapeutics president sells shares worth $3.73 million - Investing.com
Loomis Sayles & Co. L P Sells 83,408 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Idiopathic Pulmonary Fibrosis Market Report 2034, by DelveInsight | Companies: FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech - The Globe and Mail
Charles Schwab Investment Management Inc. Sells 17,838 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Swedbank AB Decreases Position in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Citigroup Inc. - MarketBeat
Intech Investment Management LLC Sells 6,815 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Thrivent Financial for Lutherans Has $5.14 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics EVP sells shares worth $2.8 million By Investing.com - Investing.com Australia
United Therapeutics EVP sells shares worth $2.8 million - Investing.com India
Zacks Research Has Optimistic Outlook of UTHR Q4 Earnings - MarketBeat
Neuroblastoma Drugs Market 2024-2031 Global Industry - openPR
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio - Yahoo Finance
Zacks Research Has Positive Outlook for UTHR FY2024 Earnings - MarketBeat
Swiss National Bank Sells 7,300 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
MannKind Shares Soar to Over 8-Year Highs on United Therapeutics’ Tyvaso Revenue Surge: Retail Is Optimistic - MSN
14,800 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by Premier Fund Managers Ltd - MarketBeat
United Therapeutics president sells shares worth $3.59 million - Investing.com
United Therapeutics president sells shares worth $3.59 million By Investing.com - Investing.com UK
Seizert Capital Partners LLC Raises Position in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Empowered Funds LLC Sells 25,412 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics: Competitive Advantages At Such Cheap Multiples Scream Buy - Seeking Alpha
United Therapeutics Expands Into Organ Transplants, But Tyvaso's Legal Battles Loom - Seeking Alpha
Entropy Technologies LP Cuts Stock Position in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Chronic Pulmonary Hypertension Market Size in the 7MM was ~USD 28,290 million in 2023, estimates DelveInsight - The Globe and Mail
1,375 Shares in United Therapeutics Co. (NASDAQ:UTHR) Purchased by Chase Investment Counsel Corp - MarketBeat
Insider Sale: Director Judy Olian Sells Shares of United Therape - GuruFocus.com
Unsatisfied With $70M UTC Win, Sandoz Appeals To 3rd Circ. - Law360
State of New Jersey Common Pension Fund D Sells 1,464 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Principal Financial Group Inc. - MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) Stock Position Lowered by Los Angeles Capital Management LLC - MarketBeat
Fiera Capital Corp Makes New $517,000 Investment in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Brokerages Set United Therapeutics Co. (NASDAQ:UTHR) Target Price at $370.86 - MarketBeat
Galvin Gaustad & Stein LLC Invests $8.96 Million in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics president sells shares worth $9.97 million By Investing.com - Investing.com Canada
United Therapeutics president sells shares worth $9.97 million - Investing.com
United Therapeutics Stock Soars to All-Time High of $413.66 - Investing.com
Philip James Wealth Mangement LLC Invests $475,000 in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Summit Global Investments - MarketBeat
United Therapeutics (NASDAQ:UTHR) Sets New 1-Year HighStill a Buy? - MarketBeat
Financial Enhancement Group LLC Makes New $6.67 Million Investment in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Amalgamated Bank Cuts Stake in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) Holdings Increased by National Pension Service - MarketBeat
United Therapeutics director Giltner sells shares worth $3.8 million - Investing.com
Insider Sale: Director Richard Giltner Sells 10,000 Shares of Un - GuruFocus.com
United Therapeutics Corp Stock (UTHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
United Therapeutics Corp Stock (UTHR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BENKOWITZ MICHAEL | PRESIDENT AND COO |
Nov 25 '24 |
Sale |
372.75 |
10,000 |
3,727,547 |
0 |
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Nov 21 '24 |
Option Exercise |
163.30 |
7,700 |
1,257,410 |
44,410 |
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Nov 21 '24 |
Sale |
367.36 |
7,700 |
2,828,672 |
36,710 |
| BENKOWITZ MICHAEL | PRESIDENT AND COO |
Nov 18 '24 |
Option Exercise |
104.33 |
10,000 |
1,043,325 |
7,500 |
| BENKOWITZ MICHAEL | PRESIDENT AND COO |
Nov 18 '24 |
Sale |
359.21 |
10,000 |
3,592,071 |
0 |
0.76%
1.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):